As a first-line lipid-lowering drug, atorvastatin has been shown to reduce AD risk possibility by upregulating liver LRP1 (Moon, Kang, Park, Lee, Kang, Ahn, Lee and Cha 2011; Zissimopoulos et al., 2017). Here, LRP1 is linked to Alzheimer disease.